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PREVENTION OF ILLNESS
Dr. Paul Bernstein'
Overusing Scans Adds to Cancer Risk, a recent Milwaukee
Too much
Journal Sentinel front page headlined warned.'
radiation increases cancer risk; though just how much radiation
is uncertain. The best estimates are based on the Chernobyl
nuclear power plant accident and studies of the Japanese atomic
bomb survivors who had excess cancer risk after exposure to
between 50 and 150 millisieverts. 2 A study last year estimated
that over four million Americans receive greater than twenty
millisieverts a year from medical imaging.3
A study from Columbia University estimated that in three
decades, two percent of all cancers may result from radiation
derived from CT scans given now. 4 If, as recent studies suggest,
thirty percent of all imaging studies are unnecessary, then more
than twenty million Americans are needlessly at risk.5 Since
many of these scans are obtained in order to prevent illness, or
detect otherwise unrecognized medical conditions, one must
wonder how much harm is wrought in the name of prevention.
*Dr.Paul Bernstein received his B.A. in 1972 and his M.D. in 1976 from
the University of Chicago. In 1982, he became a Fellow of the American
College of Cardinals, and from 1988 to 1992 was the Chief of
Cardiology at Columbia Hospital. In 1996, he completed his Master's
of Liberal Arts also from the University of Chicago. From 2000 to 2003
he was the Chief of Cardiology at St. Luke's Medical Center in
Milwaukee, Wisconsin. In 2007 he received his J.D. from Marquette
University Law School.
1. Marilynn Marchione, Overusing Scans Adds to Cancer Risk, MILWAUKEE J.
SENTINEL, June 14, 2010, at 1A.
2. Id. at 4A.
3. Id.
4. Id.
5. Id.
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INTRODUCTION

Americans cherish their health care. Many believe that health
care is a right. Overwhelmingly, Americans believe that more
health care is better care and that the more money spent, the
better the care. And so any reduction of health care or health
care dollars will lead, they believe, to poorer health.
But many doctors know better. In the catheterization
laboratory where cardiologists place stents in coronary arteries,
they know that better is the enemy of good. Numerous scientific
studies have confirmed that more is not better.
* Three anticoagulants are not better than two.6
* Intensive blood pressure lowering in diabetics is
dangerous. 7
* Intensive glycemic control is dangerous.'
* Two lipid-lowering drugs are not better than a Statin
alone.9
PHYSICIANS AND SCIENTISTS KNOW THAT MORE MEDICINE AND
MORE PROCEDURES AND MORE HEALTHCARE DOLLARS DO
NOT NECESSARILY LEAD TO BETTER HEALTH.

In November 2009, the U.S. Preventive Services Task Force
against
routine
screening
recommended
(USPSTF)
mammography in women ages forty to forty-nine and biennial
this
critics
seized
upon
Some
testing thereafter. 0

6. CLION-T: Triple Antiplatelet Therapy Associated with Improved Platelet
Reactivity, CARDIOLOGY TODAY (Mar. 15, 2010), http://www.cardiologytoday.com
/view.aspx?rlD=61972.
7. Carl Pepine et al., Rationale and Design of the International Verapamil
SR/Trandolapril Study (INVEST): An Internet-Based Randomized Trial in Coronariy
Artery Disease Patients Withi Hypertension, 32 J. AM. C. CARDIOLOGY 1228, 1233 (1998).
8. Jay S. Skyler et al., Intensive Glycenic Control and the Prevention of
Cardiooascular Evcnts: Implications of the ACCORD, ADVANCE, and VA Diabetes
Trials, 53 J. AM. C. CARDIOLOGY 298, 302 (2009).
9. See id. at 303.
10. U.S. Preventive Services Task Force, Screening for Breast Cancer: U.S.
Preventive Services Task Force Reconinendation Statement, 151 ANNALS INTERNAL MFD.
716, 716 (2009).
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recommendation as an example of the kind of "'rationing' that
would allow government bureaucrats to deny insurance
Others made
coverage of important health procedures.""
"unsubstantiated attacks on the expertise, motivations, and
independence of the scientists and clinical experts on the
USPSTF."12 In fact, both House and Senate bills had required
health plans to cover preventive services based on evidencebased reviews by USPSTF. They provided a floor, but no limit,
on essential preventive services; and, they proposed
comparative effectiveness research and prohibited the use of
such research to limit or deny coverage based on cost.13
The Obama administration distanced itself from the new
recommendations by assuring the public that government
insurance programs would cover routine mammograms for
woman starting at age forty, regardless of the Task Force
recommendations. The administration emphasized that the
Task Force recommendations are non-binding on physicians and
insurers. 14
Senator Barbara Mikulski, Democrat of Maryland,
championed an amendment that directed Health and Human
Services to issue guidelines on which preventive services private
insurers must provide free to women. 5 Senator Vitter of
Louisiana amended her amendment directing the government to
ignore the Task Force recommendations regarding routine
mammography in woman under fifty.16 The Senate approved
the measure sixty-one to thirty-nine. 17
Ultimately, the Patient Protection and Affordable Care Act

11. Editorial, Senate Health Care Follies, N.Y. TIMES, Dec. 6, 2009, at WK9.
12. Joseph W. Stubbs, Statement on the Politicization of Evidence-Based Clinical
Research, AM. C. PHYSICIANS (Nov. 24, 2009), http://www.acponline.org
/pressroom/pol ebcr.htm.
13.

Id.

14. United
States
Preventive
Services
Task
Force,
N.Y.
TIMES,
http://topics.nytimes.com/top/reference/timestopics/organizations/p/preventive_ser
vicestaskforce/index.html (last updated Nov. 20, 2009).
15. N.Y. TIMES, supranote 11.
16. Id.

17. Id.
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of 2009 (Health Care Reform Act) determined that
current recommendations of the United States
Preventive Services Task Force regarding breast cancer
screening ... shall be considered the most current other
than those issued in or around November 2009.
Nothing in this subsection shall be construed to
prohibit a plan or issuer from providing coverage for
services in addition to those recommended by [the]
United States Preventive Services Task Force.18
In response, the American College of Physicians published
an opinion paper stating that
the public is ill-served when assessments of clinical
effectiveness are politicized .

.

. such politicization, if

left unchallenged, could lead to efforts to eliminate the
Task Force, cut its funding, or result in politicallydriven changes so that future evaluations are
influenced by political or stakeholder interests - instead
of science.19
Preventive health services include screening to detect
otherwise unrecognized disease, counseling, and preventive
medications or treatments. Primary prevention aims to prevent
the development of disease not yet manifested, whereas
secondary prevention attempts to forestall the progression of
disease.
The most powerful interventions have included sanitation
and hygiene, soap and water. Vaccinations have eradicated
some diseases entirely. Vitamin C in natural or supplemental
form prevented scurvy. 20 Colonoscopy, mammography and
PSA measurement have been recommended and used for early

18. Patient Protection and Affordable Care Act of 2010, § 1001, H.R. 3590, Pub.
L. No. 111-148, 124 Stat. 119, 1 11 h Cong. (2010) (to be codified throughout 42 U.S.
Code).
19. Donna A. Sweet, Member, Am. C. Physicians Clinical Assessment Efficacy
Subcomm., Breast Cancer Screening Recommendations, Address before the House
Energy and Commerce Committee, Subcommittee on Health (Dec. 2, 2009), available
at http://energycommerce.house.gov/Press_111/20091202/sweet testimony
.pdf.
20.

Vitamin C, THE MERCK MA\UAL ONIINF, http://www.merck.com/

mmpe/sec0l/ch04/chOO4j.html?qt=vitamin%20c&alt-sh (last updated Apr. 2007).
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detection of cancer. 21 Life style modifications such as weight
loss and exercise are thought to impact the development of
Vitamin
hypertension, diabetes and heart disease. 22
supplements are taken by a large percentage of the population
with the belief that vitamins will prevent cancer and heart
disease, among other effects. Finally, treatments such as lipidlowering drugs are known to be effective in primary and
secondary prevention of atherosclerotic heart disease. 23
The "cost" of prevention is not simply dollars. When
screening X-ray studies are undertaken on a large scale, harm
may result in the form of excess cancer from radiation. 2 4 Harm
also comes in the form of pain and complications of biopsies,
and from false-positive results leading to unnecessary testing
and surgeries and psychological trauma. All treatments have
complications, some lethal, others with profound impact on the
quality of life. Most of all, there is harm from "over-diagnosis,"
defined as treatment of a disease that never would have hurt the
patient. We will return to this important concept below.
In the following pages we will examine the U.S. Preventive
Services Task Force in detail. Then we will discuss the
controversial topics of screening mammography for breast
cancer and PSA screening for prostate cancer. Then, we will
turn our attention to lifestyle modification and obesity, and
finally vitamin supplementation. We will show that more care is
not necessarily better care and that assessments of clinical
effectiveness cannot be politicized or risk being misguided. And
in our rush to provide expensive health care, we should not lose
sight of basic health measures such as exercise and diet.

21. Cancer Screening, THE MERCK MANUAL ONLINE, http://www.merck.com

/mmpe/sec11/chl47/chl47d.html?qt-cancer%20screening&alt-sh
2008).

(last updated Aug.

22. Obesity, THE MERCK MANUAL ONLINE, http://www.merck.com

/mmpe/sec01/ch006/ch006a.html?qt-obesity&alt-sh (last updated Oct. 2008).
23. Dyslipidemia, THE MERCK MANUAL ONLINE, http://www.merck.com
/mmpe/secl2/chl59/chl59b.html?qt-dyslipidemia&alt-sh (last updated Sept. 2008).
24. Marchione, supra note 1, at 1A.
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THE U.S. PREVENTATIVE SERVICES TASK FORCE

The U.S. Preventative Services Task Force (hereinafter "Task
Force") was first convened by the U.S. Public Health Service in
1984. Since 1998, it has been sponsored by the Agency for
Healthcare Research and Quality (AHRQ). The panel is
composed of leading experts in prevention and primary care. Its
members are drawn from the private-sector. The Task Force
examines the scientific evidence for the efficacy of clinical
preventive services, including preventive medications and
treatments, counseling, and screening. Its studies are unbiased,
independent, and meticulous. Clinicians and scientists consider
its recommendations the "gold standard" of preventive health
services. 25
In short, the mission of the Task Force is to evaluate the
benefits of preventive services, recommend which services
should be incorporated into medical care and for whom, and
develop a research agenda for clinical preventive care. 26
As a matter of law, AHRQ must convene the Task Force to
conduct reviews of scientific evidence on a wide array of clinical
preventive services.2 7 The Task Force is charged with developing
recommendations for health care providers and for providing
administrative, research, and technical support. 28
The Task Force employs explicit criteria to make its
recommendations which are intended for use by primary care
physicians. Recommendation statements present providers with
the evidence, allowing them to make informed decisions. 29
The Evidence-based Practice Center (EPC) supports the
Task Force. The EPC, under contract to the AHRQ, conducts
systematic and scientific reviews of the evidence that serve as

FORCE,
SERVS.
TASK
U.S.
PREVENTATIVE
the USPSTF,
25. About
http://www.uspreventiveservicestaskforce.org/about.htm (last updated Sept. 2010).
26. Id.
27. 42 U.S.C. § 299b-4(a)(1) (2010).
28. U.S. PRFVENTATIVE SERvS. TASK FORCE, supra note 25.
29. Id.
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the basis for the Task Force recommendations. 30 In turn, the Task
Force examines the evidence, weighs the relative benefits and
harms of the recommended preventive service, and issues a
recommendation. The Task Force, after weighing the evidence,
"grades the strength of the evidence, from 'A' (strongly
recommends), 'B' (recommends), 'C' (no recommendation for or
against), 'D'(recommends against), or 'I'(insufficient evidence to
recommend for or against)."3 1
It is important to note the many "partners" to the Task
Force. They include primary care academies, Family Physicians
(AAFP), Nurse Practitioners (AANP), Pediatrics (AAP),
Physician Assistants (AAPA), OB-Gynecologists (ACOG),
American College of Physicians (ACP), and others. They also
include policy improvement partners such as AARP and the
National Committee for Quality Assurance. Federal partners
include the Centers for Disease Control and Prevention (CDC),
the Centers for Medicare and Medicaid Services (CMS), the U.S.
Food and Drug Administration (FDA), the National Institutes of
Health (NIH), Veteran's Health Administration (VHA), and
others. 32
The Task Force recommendations buttress prevention in
primary care, provide the basis for insurance coverage, and hold
physicians and providers accountable for the delivery of
effective care.
But, the Task Force does not consider economic costs in making
recommendations, though it researches cost effectiveness and
reports this information separately. These recommendations are
not modified to accommodate concerns about insurance
coverage of preventive services, medical-legal liability, or
legislation.33

30. Id.
31. Id.
32. Id.
33. U.S. Preventive Services Task Force (USPSTF) Procedure Manual - Section 5:
Methods for Arriving at a Recommendation, U.S. PREVENTIVE SERVS. TASK FORCE,
http://www.uspreventiveservicestaskforce.org/uspstf08/methods/procmanual5.htm
(last updated July 2008).
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2009

For woman, the most frequently diagnosed cancer in the United
States is breast cancer, which is "second only to lung cancer as a
cause of cancer deaths.

In 2008, . . . 182,460 cases of invasive

cancer and 67,770 cases of in situ breast cancer were diagnosed
and 40,480 breast cancer deaths occurred." 4
During their lifetime, one in eight women will develop
breast cancer, the risk increasing with age. The ten-year risk is
one in sixty-nine for a woman at age forty, one in forty-two at
age fifty, and one in twenty-nine at age sixty.3 5 The incidence
rate for breast cancer may be decreasing, most likely due to
discontinuation of hormone replacement therapy. And, breast
cancer mortality has been decreasing. This has been attributed
to better treatment and screening mammography. 36
In 2009, Health and Human Services asked the Task Force
to reassess its 2002 recommendations on breast cancer screening.
A sixteen-member task force was convened by HHS, which in
turn asked the Evidence-Based Practice Center at Oregon Health
and Science University for an extensive review of relevant
papers on breast cancer screening. The Oregon scientists sent
the request out to fifteen outside scientists for additional review,
and then returned their analysis back to the panel.37
In November 2009, the Task Force updated its 2002
recommendations on mammography, recommending against
routine screening in women ages forty to forty-nine.38 The
decision to start earlier than age fifty is an individual one, based
on patient context and values, it stated.39 The Task Force made
another significant change in long-standing recommendations,

34. USPSTF, supra note 10, at 720.
35. Id.
36. Id.
37. Gina Kolata, Behind Cancer Guidelines, Quest for Data, N.Y. TIMES, Nov. 23,
2009, at A19.
38. U.S. Preventive Services Task Force, supra note 10, at 716.
39. Id.
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to biennial screening in woman ages fifty to seventy-four. 40 It
concluded that evidence is "I" (insufficient) to recommend
screening in women over age seventy-five, and "I" (insufficient)
for the routine use of magnetic resonance and digital
mammography.4 1
The 2002 the Task Force had issued a B recommendation for
screening mammography for women forty years of age or
older 4 2 (a "B" grade means that the Task Force recommends the
service; there is a high certainty that the net benefit is moderate
or there is moderate certainty that the net benefit is moderate to
substantial).4 However, it went on to say that "[t]he precise age
at which the benefits from screening mammography justify the
potential harms is a subjective judgment and should take into
account patient preferences.""
It advised clinicians to tell
patients that the balance of benefits and potential harms of
mammography improves with increasing age. 4 5
The updated 2009 Task Force recommendations were
heavily influenced by a new review in which was included a
randomized controlled trial. In that study, the number needed to
screen to extend one woman's life was 1904 for women aged
thirty-nine to forty-nine compared with 1339 for women aged
fifty to fifty-nine. 46 Because the risk for breast cancer rises
sharply with age, even though the relative risk reduction was
nearly the same for these age groups (15% and 14%), the
absolute risk reduction for the fifty to fifty-nine year-old women
compared with the forty to forty-nine year-old cohort is
greater.47
The update was also influenced by a technical study that

40. Id.
41. Id.
42. Id. at 719.
43. U.S. PREVENTATIVE SERVS. TASK FORCE, supra note 25.
44. U.S. Preventive Services Task Force, supranote 10, at 719.
45. Id.
46. Heidi D. Nelson et al., Screening for Breast Cancer: An Update for the U.S.
Preventive Services Task Force, 151 ANNALS INTERNAL MED. 727, 730 (2009).
47. Id. at 719.
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compared mortality rates when screening was started at forty
and fifty years of age. This analysis also demonstrated that large
numbers of mammograms during the forties led to little gain in
life. 48
Put simply, in terms of NNS (numbers needed to screen),
1904 woman ages thirty-nine to forty-nine must be screened to
prevent one death from breast cancer after at least eleven years
of observation, compared to 1339 women in their fifties and 377
women in their sixties.49
As was stressed above, the Task Force does not consider
economic issues when making recommendations. 50 However,
cost analysis is another way to get at relative and absolute
benefit. Traditionally, this is done by looking at "years of life
saved." One such study compared the life expectancy of women
who were screened for breast cancer. The authors found that it
cost $105,000 per year of life saved for women in their forties
compared with $21,000 for women in their fifties or sixties. So,
the cost of screening for one year of life saved for women in their
forties is five times that of older women. That said, both are
within a generally accepted range of cost-effectiveness.
BENEFITS VS. HARMS

The Task Force had to weigh the benefits against the potential
harms of screening: Women in their forties have a 10% chance of
having a false positive screen. 2 They have a 1% biopsy rate for
each mammogram. 53 Yet their risk of cancer is only 1.5 per 1000
women.5' The anxiety and stress that occurs with a false positive
48. Jeanne S. Mandelblatt et al., Effects of Mammography Screening Under
Different Screening Schedules: Model Estimates of Potential Bcnefits and Haris, 151
ANNALS INTERNAL MED. 738, 744 (2009).
49. Nelson, supra note 46, at 729-30.
50. USPSTF ProcedureManual, supra note 33.
51. Peter Salzmann et al., Cost Effectiveness of Extending Screening Mammography
Guidelines to Include Wouen 40 to 49 Years of Age, 127 ANNALS INTERNAL MED. 955,
961 (1997).
52. Kolata, supra note 37.
53. Id.
54. Id.
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mammogram is common but usually short lived."
Over-diagnosis can occur when screening detects DCIS
(ductal carcinoma in-situ), usually in an older woman, who is
more likely to die from another cause before the breast cancer
would be clinically evident.5 6 It also occurs when ductal
carcinoma or another early-stage lesion never progresses to
invasive cancer.57 Another form of over-diagnosis is when
screening detects a slowly growing cancer that may have never
been clinically evident or caused death.58 Methods for
determining over-diagnosis are not well established. 9
Thus, over-diagnosis occurs in the setting of three kinds of
cancer: cancers growing so fast that early diagnosis is futile;
cancers growing so slowly they need not be found early to be
cured - estimated at one in four; and cancers that can be cured if
found early - estimated at 15% of cancers. 60 It is estimated that
as many as 30% of cancers found by screening in women in their
forties are over-diagnosed. 61
The surgery, radiation, and chemotherapy that occur
without benefit in the setting of over-diagnosis cannot be
accurately calculated and must offset whatever benefits come
with screening in the young.
The Task Force concluded "that the additional benefit
gained by starting screening at age 40 years rather than at age 50
years is small, and that moderate harms from screening remain
at any age." 62 Thus, the Task Force gave a "C" recommendation
to early screening (a "C" grade is a recommendation against

55. Nelson, supra note 46, at 734.
56. Sue Moss, Overdiagnosis in Randomised Controlled Trials of Breast Cancer
Screening, 7 BREAST CANCER RES. 230, 230 (2005).
57. H. Gilbert Welch et al., The Sea of Uncertainty Surrounding Ductal Carcinoma
In Situ - The Price of Screening Mammography, 100 J. NAT'L CANCER INST. 228, 228
(2008).
58. Id.
59. Id.

60. Kolata, supra note 37.
61. Id.
62. USPSTF, supra note 10, at 719.
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routine screening of women aged forty to forty-nine). 63
Assessing risk, the Task Force found that mammograms
every two years give the same benefit as annual mammograms;
but, confer half the risk of harms. 64
In response
to the
storm
of controversy
its
recommendations produced, the Task Force quickly amended
them. In December 2009, it dropped its recommendation against
routine screening in women ages forty to forty-nine, substituting
a more nuanced statement: "The decision to start regular,
biennial screening mammography before the age of 50 years
should be an individual one and take patient context into
account, including the patient's values regarding specific
benefits and harms." 65 Thus, despite a careful scientific analysis
by independent, private-sector scientists, the Task Force
recommendation to delay mammography until age fifty was
dropped.6 6 Whether this action occurred for political or
emotional reasons is left for the reader to decide.
Numerous organizations have issued breast cancer
screening recommendations. Given the controversy, it may be
useful to consider them. One must keep in mind that these
recommendations are for those who are not at increased risk, i.e.
who are not genetically at risk. 67
The American Cancer Society recommended annual
mammography at age 40 in a statement issued in 2003.68 In the
days following the November '09 Task Force recommendation
that screening mammography not be routinely done before age
fifty, 69 the American Cancer Society stated that it "continues to

63. Id.
64. Id. at 718.
65. Screening for Breast Cancer, U.S. PREVENTIVE SERvS. TASK FORCE,
(last updated
http://www.uspreventiveservicestaskforce.org/uspstf/uspsbrca.htm
Dec. 2009).
66. Id.
67. Gina Kolata, Panel Urges Mammograms at 50, Not 40, N.Y. TIMES, Nov. 17,
2009, at Al.
68. Robert A. Smith et al., American Cancer Society Guidelines for Breast Cancer
Screening: Update 2003, 53 CANCER J. FOR CLINICIANS 141, 142 (2003).
69. U.S. Preventive Services Task Force, supra note 10, at 716.
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recommend annual screening using mammography and clinical
breast examination for all women beginning age 40."7o The
American Cancer Society took issue with the conclusions made
by the Task Force, particularly that screening 1904 women in
their forties in order to save one life was not worthwhile. Dr.
Otis Brawley, the Chief Medical Officer of the American Cancer
Society acknowledged that recommendations are based on
judgments about the balance of benefits and risks and that
reasonable experts can look at the same information and reach
different conclusions.71
The American Medical Association in 2002,72 and the
National Comprehensive Cancer network in 2009,73 have made
recommendations similar to those of the American Cancer
Society. The American Academy of Family Physicians has
previously endorsed the Task Force recommendations on breast
cancer screening. 74 The American College of Physicians in 2007
recommended that screening mammography decisions in
women forty to forty-nine years should be individualized and
based on risk of breast cancer; that women should be informed
about risks and benefits of screening mammography; and that
physicians should base their decisions on benefits and harms, as
well as the individual patients preferences and risk factor
profile.75 In 2003, the American College of Obstetrics and
Gynecology recommended mammography every one to two
years for women aged forty to forty-nine and annually after age
70. Press Release, Am. Cancer Soc'y, American Cancer Society Responds to
Changes to USPSTF Mammography Guidelines (Nov. 16, 2009), available at
http://pressroom.cancer.org/index.php?s-43&item=201.
71. Id.
72. AMA Policies on Breast Cancer, AM. MED. ASS'N, http://www.amaassn.org/ama/no-index/about-ama/9060.shtml (last visited Nov. 15, 2010).
73. See generally NAT'L COMPREHENSIVE CANCER NETWORK, NCCN CLINICAL
PRACTICE GUIDELINES IN ONCOLOGY: BREAST CANCER SCREENING AND DIAGNOSIS

V.1.2009 (2009).
74. A-E: Recommendations for Clinical Preventive Services, AM. ACAD. FAMILY
(last visited
PHYSICIANS, www.aafp.org/online/en/home/clinical/exam/a-e.html
Nov. 15, 2010).
75. Amir Qaseem et al., Screening Mammographyfor Women 40 to 49 Years of Age:
A Clinical Practice Guideline from the American College of Physicians, 146 ANNALS
INTERNAL MED. 511, 511-12 (2007).
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fifty. 76 In 2009, the World Health Organization recommended
mammography every one to two years for women aged fifty to
sixty-nine years.77
Thus, recommendations for breast cancer screening
mammography are mixed, with movement away from routine
screening for women aged forty to forty-nine and toward
individualizing screening recommendations based on a
thorough discussion of benefits and harms and with the
individual patient's preferences and risk profile in mind.
SCREENING FOR PROSTATE CANCER

Prostate cancer is the most commonly diagnosed male
malignancy in the U.S.78 In 2008, more than 186,000 cancer cases
were predicted to be diagnosed and more than 28,000 are likely
to die." After lung cancer, prostate cancer is the leading cause of
death from cancer for men.s0
Prostate cancer must be understood in terms of the
following statistics: Even though the risk of developing prostate
cancer is high, roughly one in six, the risk of dying from it is
only 2.9%. This implies an indolent course for a significant
percentage of patients and should inform treatment strategies.
In fact, at autopsy, one-third of men under age eighty and twothirds of older men have evidence of prostate cancer. " Thus, for
many patients, the cancer grows so slowly that they die from
other causes and for most, it is a post-mortem diagnosis.8 2
The PSA (prostate-specific antigen) was initially developed
76. American College of Obstetricians and Gynecologists Committee on
Practice Bulletins, ACOG PracticeBulletin: Breast Cancer Screening, 101 OBSTETRICS &
GYNECOLOGY 821, 826 (2003).

77. U.S. Preventive Services Task Force, supra note 10, at 722.
78. Eric A. Klein, Prostate Cancer: Progression,Risk Reduction, and Future Options,
4 RFVS. UROLOGY S1, S1 (Supp. 2002).
79. Ahmedin Jemal et al., Cancer Statistics, 2008, 58 CANCER J. FOR CLINICIANS
71, 73 tbl. 1 (2008).
80. Id.
81. Victoria J. Dorr et al., An Evaluation of Prostate- Specific Antigen as a Screening
Test for Prostate Cancer, 153 ARCH IVES INTERNAL MED. 2529, 2529 (1993).
82. See id.
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to follow the course of prostate cancer. However, it quickly
became a screening tool. 3 Because of this screening, the
incidence of prostate cancer rose rapidly. Despite what we
stressed above, that prostate cancer is usually slow growing, and
that patients usually die from other causes, the increase in
diagnoses was coupled with an increase in treatments, many
fairly aggressive. These included external radiation and radical
prostatectomy. 84 Unfortunately, PSA testing was adopted before
its benefit was demonstrated from randomized trials. Its use
now is more controversial than ever.
In August 2008, the Task Force issued a recommendation
statement on screening for prostate cancer. 5 "The USPSTF found
convincing evidence that prostate-specific antigen (PSA)
screening can detect some cases of prostate cancer."8 6 In men
under seventy-five years, the Task Force found insufficient
"evidence to determine whether treatment for prostate cancer
detected by screening improves health outcomes compared with
treatment after clinical detection." 7 In men age seventy-five or
older the Task Force found "that the incremental benefits of
treatment for prostate cancer detected by screening are small to
Prostate cancer treatments resulting from PSA
none." 8
screening cause "moderate-to-substantial" harms because so
many men treated would not have had clinically detected cancer
in their lifetimes, the Task Force concluded. These harms include
erectile dysfunction in 20% to 70% percent, urinary incontinence
in 20% to 50%, bowel problems and death.89
The American Cancer Society has urged men to be informed

83. Fritz H. Schroder, Screening and Prostate-Cancer Mortality in Randomized
European Study, 360 NEw ENG. J. MED. 1320, 1321 (2009).
84. Grace L. Lu-Yao & E. Robert Greenberg, Changes in Prostate Cancer Incidence
and Treatment in USA, 343 LANCET 251, 251 (1994).
85. See generally U.S. Preventive Services Task Force, Screening for Prostate
Cancer: U.S. Preventive Services Task Force Recommendation Statement, 149 ANNALS
INTERNAL MED., 185 (2008).
86. Id. at 185.
87. Id.
88. Id.
89. Id. at 185-86.
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before deciding to have a PSA test.90 Two recent trials published
together on March 26, 2009, in the prestigious New England
Journal of Medicine now provide information with which to
inform patients. In both studies, participants were randomly
assigned to be screened, or not, with PSA. Both groups were
then followed for more than a decade while deaths from
prostate cancer were counted, so as to learn whether screening
makes a difference.9 '
In order to evaluate the impact of PSA screening and digital
rectal exams on the course of prostate cancer, The Prostate,
Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
randomly assigned 76,693 men at ten U.S. centers to receive
either annual screening or usual care as the control. 92 Subjects in
the screening group were offered PSA testing for six years and
digital rectal exam for four years.93 Usual care might include
this screening. The endpoints were numbers of all cancers and
deaths.
In the screening group, 85% had PSA testing and 86% had
digital rectal exams. In the control group, rates of screening
with PSA varied from 40% to 52% and rates of digital
examination varied from 41% to 46%. There were 116 cancers
per 10,000 person-years and 50 deaths in the screening group
compared with 95 cancers per 10,000 person-years and 44 deaths
in the control group. 94
After seven to ten years of follow-up, the rate of death from
prostate cancer was quite low and did not differ significantly
between the two study groups.95
The second study began in the 1990s and was also designed
to evaluate the benefit of PSA screening. The endpoint was

90. Id. at 188.
91. Gerald L. Andriole et al., Mortality Results from a Randomized Prostate-Cancer
Screening Trial, 360 NEw ENG. J. MFD. 1310, 1311 (2009); Schroder, supra note 83, at
1321.
92. Andriole, supra note 91, at 1311, 1313.
93. Id. at 1311.
94. Id. at 1313-14.
95 Id. at 1314.
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death from prostate cancer. The European Randomized Study
for Screening for Prostate Cancer enrolled 182,000 men ages fifty
to seventy-four years. They were randomly assigned to a control
without PSA screening and a group that received the PSA on an
average of every four years. 96 Those screened had fewer deaths
from prostate cancer, but the absolute risk was only 0.71 per
1000 men. After screening 1410 men and treating forty-eight
cancers, one death is prevented. For 10,000 men screened over
nine years, seven lives are saved from prostate cancer.97
The researchers concluded that "PSA . . . screening reduced

the rate of death from prostate cancer by 20% but was associated
with a high risk of over-diagnosis." 98 Over-diagnosis refers to
the fact that forty-eight men were treated for prostate cancer
without benefit, "for every man whose death was prevented
within a decade after having had a PSA test."99
Peter Bach, a physician and epidemiologist at Memorial
Sloan-Kettering Cancer Center interpreted the data for the New
York Times. 0o If a man has a PSA test that is positive, has a
biopsy that reveals prostate cancer, and is treated for it, he said,
[t]here is a one in 50 chance that, in 2019 or later, he will
be spared death from a cancer that would otherwise
have killed him. And there is a 49 in 50 chance that he
will have been treated unnecessarily for a cancer that
was never a threat to his life.10
Dr. Otis Brawley, the Chief Medical Officer of the American
Cancer Society said, "'[t]he [PSAJ test is about 50 times more
likely to ruin your life than it is to save your life."1 02 Ironically,
he is the very same person who criticized the Task Force for
finding that mammography screening 1904 women in their
96. Schroder, supra note 83, at 1320.
97. Id.
98. Id.
99. Gina Kolata, Studies Show Prostate Test Saves Few Lives, N.Y. TIMES, Mar. 19,
2009, at Al.
100. Id.
101. Id.
102. Tara Parker-Pope, Screen or Not? What Those Prostate Studies Mean, N.Y.
TIMES, Mar. 24, 2009, at D5.
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forties in order to save one life was not worthwhile. 103
It might be reasonable to conclude that PSA screening
uncovers prostate cancer that is growing too slowly to matter, or
too fast to impact its course. And, like screening mammography
for women in their forties, this screening test is a personal
choice.
The American Cancer Society does not recommend routine
PSA screening for most men; rather, the Society urges doctors to
discuss pros and cons of the screening on an individual basis.
The Cancer Society does not recommend the digital rectal exam
because it has not shown benefit." 4
LIFE STYLE MODIFICATION: OBESITY

"[T]wo thirds of U.S. adults and one fifth of . . . children are

obese or overweight."1 0 5 From 1980-2004, obesity prevalence
among adults doubled. Thirty-three percent of U.S. adults are
overweight (BMI 25-29). Thirty-four percent are obese (BMI
greater than or equal to 30).106 "[Seventeen percent] of U.S.
children and adolescents are overweight." 1 7 Obesity increases
risk for many diseases including heart disease, type 2 diabetes
(non-insulin requiring), certain cancers, and stroke. 10s
Certain environmental factors are thought to impact the
incidence of obesity, "including lack of access to full-service
grocery stores" with fruits and vegetables, "increas[ed] costs of
healthy foods and ... lower costs of unhealthy foods, and lack of

access to safe places to play and exercise." 10 9 Reversing the
103. Am. Cancer Soc'y, supra note 70 and text accompanying note 71.
CANCER SOC'Y,
Found Early?, AM.
104. Can Prostate Cancer be
http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/prostate-cancerdetection (last updated Nov. 22, 2010).
105. Laura Kettel Khan et al., Recoimmended Connunity Strategies and
Mcasurenents to Prevent Obesity in the United States, CTRS. FOR DISEASE CONTROL,
7
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr580 al.htm (last updated July
14, 2009).
106. Id.
107. Id.
108. Id.
109. Id.
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obesity epidemic will require "a comprehensive and coordinated
approach that uses policy and environmental change to
transform communities into places that support . . . [a] healthy

lifestyle."110
Recently the Center for Disease Control (CDC) "initiated the
Common Community Measures for Obesity Prevention Project
(the Measures Project)."'" The objective was to identify and
recommend strategies and measurements that communities "can
use to plan and monitor environmental and policy-level changes
for obesity prevention."' 1 2 The Measures Project developed a
number of strategies to reduce the incidence of obesity: promote
availability of affordable healthy food and beverages; support
healthy food and beverage choices; encourage breastfeeding;
encourage physical activity and limit sedentary activity among
children and youth; and create safe communities that support
physical activity.113
VITAMIN D DEFICIENCY AND SUPPLEMENTATION

The scientific method is the primary strategy by which medical
First, a
researchers verify that treatments are beneficial.
Then an
hypothesis is used to explain an observation.
experiment is devised to prove the hypothesis. In the case of
medical research, the preferred experiment is a randomized,
prospective study comparing a treatment with a placebo.
A classic example of this process is the recent hormone
replacement story. Epidemiologists had "observed" that women
develop coronary artery disease a decade after men and almost
always after menopause. Scientists "hypothesized" that a fall in
hormones was responsible, and the age of hormone replacement
began. But the truth was not learned until the hypothesis was
tested years later in the Woman's Health Initiative. Published in

110. Id.

111. Id.
112. Id.
113. Id.
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2002, the WHI-funded study revealed that those postmenopausal women treated with a combination of estrogen and
progesterone actually had a higher incidence of heart attack,
stroke, and breast cancer than those not taking hormone
replacements.' 14
Severe deficiency in vitamin D results in osteomalacia in
adults and Rickets in children. But the finding that vitamin D
receptors are located in most tissues has led to an understanding
that vitamin D plays a role beyond calcium absorption and bone
metabolism."' More recent epidemiologic studies have
demonstrated that vitamin D deficiency is associated with a
number of chronic illnesses and that these illnesses occur with
greater frequency in the northern latitudes.'1 6 In this section we
will examine these observations, the evidence to support
vitamin D deficiency as causative, and the evidence for
supplementation. Is vitamin D deficiency in chronic disease an
association or a cause? Does vitamin D supplementation reduce
the incidence of heart disease, cancers, chronic infections, and
immunologic diseases?
Vitamin D is the only vitamin that is synthesized by the
human body. Upon exposure to UV radiation in the skin, 7dehydrocholesterol is converted to Vitamin D3, accounting for
more than eighty percent of vitamin D. Vitamin D2 is derived
from dietary sources such as the oily fish - salmon and herringand certain plants in which irradiation converts ergosterol to D2.
Milk, cereal, and some other foods in this country are fortified
with vitamin D; however, for most individuals, dietary intake

114. Jacques E. Rossouw et al., Risks and Benefits of Estrogen Plus Progestin in
Healthy Postmenopausal Women: Principal Results from the Women's Health Initiative
Randomized Controlled Trial, 288 JAMA 321, 322, 330.
115. Michael F. Holick, Vitamin D Deficiency, 357 NEW ENG. J. MED. 266, 266
(2007).
116. William B. Grant, Ecologic Studies of Solar UV-B Radiation and Cancer
Mortality Rates, in RECENT RESULTS IN CANCER RESEARCIH: VITAMIN D ANALOGS IN
CANCER PREVENTION AND THERAPY 372 (Jorg Reichrath et al. eds., 2003); Armin
Zittermann et al., Putting Cardiovascular Disease and Vitamin D Insufficiency into
Perspective, 94 BRIT. J. NUTRITION 483, 484, 486-87 (2005).
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does not come close to providing even the RDA of 400 IU.111
Vitamin D is converted to the inactive 25(OH)D in the liver
and is hydroxylated to its biologically active form in the kidney,
1,25(OH)2D. The active form is bound by vitamin D receptors
found not only in intestines and bone but also in most tissues,
including breast, colon, and prostate where it regulates cell
growth and differentiation."
The inactive metabolite 25(OH)D is used to measure
vitamin D levels in the serum. A level of 30 ng per millimeter is
defined as "sufficient," based on vitamin D and parathyroid
homeostasis. However, optimal levels for non-calcium related
regulation are unknown and may be higher.119 If a serum level
of 30 ng is sufficient, then there may be as many as one billion
people in the world who are deficient.120 Those at highest risk
for vitamin D deficiency include Hispanics, blacks, the obese,
and those with more skin pigment. Individuals with poor
dietary intake, the elderly, nursing home residents, and those
with chronic liver and kidney disease are also at increased
risk.121
Recent studies have linked vitamin D and total mortality.
Epidemiological studies have demonstrated that mortality from
chronic conditions such as cardiovascular disease and cancer
rises in the northern latitudes. 122 Survival of certain cancer
patients is increased if the diagnosis is made during
summertime.123 Epidemiologists have linked these observations
to vitamin D. Their theories are buttressed by recent scientific
findings that the active form of vitamin D regulates cell growth

117. Sarah A. Stechschulte et al., Vitamin D: Bone and Beyond, Rationale and
Recommendationsfor Supplementation, 122 AM. J.MED. 793, 793-94 (2009).
118. Id.
119. Holick, supra note 115, at 267.
120. Id.
121. Stechshulte et al., supra note 117, at 794-95.
122. Philippe Autier & Sara Gandini, Vitamin D Supplementation and Total
Mortality: A Meta-analysis of Randomized Controlled Trials, 167 ARCHIVES INTERNAL
MED. 1730, 1730 (2007).
123. Hyun-Sook Lim et al., Cancer Survival Is Dependent on Season of Diagnosisand
Sunlight Exposure, 119 INT'L J. CANCER 1530,1530 (2006).
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and differentiation and angiogenesis, factors relevant in cancer

formation.124
Melamed et al. examined the association between 25(OH)D
levels and the risk of mortality in the general population.125
Vitamin D levels were collected from participants in the Third
National Health and Nutrition Examination Survey from 1988
through 1994. The subjects were followed for mortality through
2000. A 25(OH)D deficiency was associated with increasing age,
higher BMI, smoking, non-white race/ethnicity, diabetes, and
female gender, whereas non-winter season, increased physical
activity, and vitamin D supplementation were inversely
associated with deficiency. The lowest quartile of vitamin D
level was associated with a twenty-six percent increase in allcause mortality in the general population compared with the

highest quartile. 126
Autier performed a meta-analysis of randomized controlled
trials examining the effect of vitamin D supplementation on total
mortality.12 7 He included eighteen trials that tested vitamin D
supplementation on any health condition, in over 57,000
subjects. The average daily dose of vitamin D was 528 IU. He
concluded that vitamin D supplementation was associated with
a decrease in total mortality, but with a narrow statistical edge. 128
However, these studies did not include mortality as a primary
endpoint and the conclusion is questionable.
The Women's Health Initiative was the only randomized
controlled study that examined vitamin D and mortality. The
trial included 36,000 postmenopausal women who were given
calcium and vitamin D or placebo. The hazard ratio for
mortality was 0.91 and did not quite achieve statistical
significance. In retrospect, the study design may have suffered
124. Paloma Ordonez-Moran et al., Vitamin D and Cancer: An Update of In Vitro
and In Vivo Data, 10 FRONTIERS IN BIOSCIENCE 2723, 2724-26 (2005).
125. See generally Michal L. Melamed et al., 25-Hydroxyvitamin D Levels and the
Risk of Mortality in the General Population, 168 ARCHIVES INTERNAL . 1629 (2008).
126. Id.
127. Autier & Gandini, supra note 122, at 1730.
128. Id.
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from the relatively low dose of vitamin D used. 12 9
The LURIC trial investigated patients scheduled for
coronary angiography. After a mean of 7.7 years, all-cause
mortality was sixty percent higher in patients from the lowest
quartile of vitamin D levels compared with the top quartile.1 11
In a Japanese study following 1232 postmenopausal
women, low levels of 25(OH)D levels was independently related
to all-cause mortality after an average follow-up of 6.9 years.131
In summary, there is data linking vitamin D deficiency with
excess mortality; however, there is insufficient evidence that
supplementation with vitamin D reduces all-cause mortality.
There is strong epidemiologic evidence connecting vitamin
D deficiency to excess cancer mortality, including colon, breast,
ovarian, and prostate cancer.132 Although the basic science
providing a hypothetical basis for this relationship is beyond the
scope of this paper, there is increasing evidence that vitamin D is
a primary regulator of cellular growth and proliferation as well
as apoptosis and angiogenesis - processes involved with tumor
formation. 3 3 Several types of cancer cells carry the receptor for
calcitriol, the active form of vitamin D. Vitamin D has been
shown to inhibit the growth of prostate cancer cells in vitro,
although at doses that result in hypercalcemia when used in in
vivo animal studies.134
In 1936, Peller noted an inverse relationship between the
frequency of skin cancer and other cancers and hypothesized

129. Andrea Z. LaCroix et al., Calcium Plus Vitamin D Supplementation and
Mortality in Postmenopausal Women: The Women's Health Initiative Calcium-Vitamin D
Randomized Controlled Trial, 64A J. GERONTOLOGY 559, 559, 566 (2009).
130. Harald Dobnig et al., Independent Association of Low Serum 25Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Levels with All-Cause and
CardiovascularMortality, ARCHIVES INTERNAL MED. 1340, 1340-42 (2008).
131. Tatsuhiko Kuroda et al., Contributionsof 25-Hydroxyvitamin D, Co-morbidities
and Bone Mass to Mortality in Japanese Postmenopausal Women, 44 BONE 168, 168, 170
(2009).
132. Cedric F. Garland et al., The Role of Vitamin D in Cancer Prevention, 96 AM. J.
PUB. HEALTH 252, 252 (2006).
133. Ordonez-Moran et al., supra note 124, at 2724, 2726.
134. Srinivasan Vijayakumar, Clinical Trials Involving Vitamin D Analogs in
ProstateCancer, 11 CANCER J.362, 363-64 (2005).
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that sunlight was the root cause. 13 5 People living further from
the equator are at increased risk for a number of cancers.13 6 Low
levels of vitamin D are associated with a 30% to 50% increase in
risk of breast, prostate and colon cancer.137 Blacks have lower
levels of vitamin D than whites and when measured in major
Midwest cities, they have rates of colon cancer that are
significantly higher than whites. 138 Blacks also have a higher
mortality rate than whites for breast cancer.139
Vitamin D levels and intake are inversely related to colon
cancer risk in numerous epidemiologic studies.140 In the
Women's Health Initiative, subjects with vitamin D levels below
12 ng had a 253 percent increased risk of colon cancer.141 Recall
that in that study, at the doses of vitamin D used, there was no
reduction in mortality from colon cancer.142 In the Nurses
Health Study, colon cancer incidence was inversely related to
vitamin D levels.143
Numerous studies have demonstrated that women who
consume more vitamin D or live in sunny areas are at lower risk
of breast cancer; and likewise, that woman with lower vitamin D
levels are at greater risk for breast cancer.144 In the Women's
Health Initiative discussed above, a nested case-control study
was performed in order to examine the influence of vitamin D
supplementation on the incidence of breast cancer. There
appeared to be no reduction of breast cancer; furthermore, levels

135. Id. at 363.
136. Frank L. Apperly, The Relation of Solar Radiation to Cancer Mortality in North
America, I CANCER RES. 191, 194 (1941).
137. See generally Edward Giovannucci et al., Prospective Study of Predictors of
Vitamin D Status and Cancer Incidtnce and Mortality in Mcn, 98 J.NAT'L CANCER INST.
451 (2006).
138. Garland, supra note 132, at 253.
139. Id.
140. Id. at 252, 253-54.
141. Holick, supra note 115, at 271.
142. LaCroix, supra note 129, at 559.
143. Diane Feskanich et al., Plasma Vitamin D Metabolites and Risk of Colorectal
Cancer in Women, 13 CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 1502, 1502
(2004).
144. Garland, supra note 132, at 254.
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of vitamin D did not correlate with breast cancer risk.14 5
Although the authors acknowledge the epidemiologic evidence,
they cite numerous negative studies. The authors are quick to
point out that a limitation of the study may have been the
relatively low dose of vitamin D provided. 46
In summary, a large body of epidemiologic evidence points
to an association between vitamin D deficiency and cancer; but
whether this is a mere association or somehow causative is
unclear. A body of basic science forms the basis for the
There is
hypothesis that the relationship is causative.
insufficient evidence that supplementation is beneficial.
Cardiovascular disease is more prevalent in northern
latitudes where vitamin D levels are lowest and more common
in the winter months. 147 Low levels of vitamin D are found in
heart failure and stroke patients and are associated with
hypertension, diabetes and obesity.148 In the Third National
Health and Nutrition Examination Survey, there was a strong
relationship between vitamin D deficiency and self-reported
cardiovascular disease. 149
Vitamin D reduces the sensitivity of the renin-angiotensin
neuro-endocrine response, inhibits cell proliferation of the
It has an antivascular lining, and regulates insulin.
150
Calcitriol, the biologically active form of
inflammatory effect.
vitamin D exerts its influence on almost all tissues through
VDR's or vitamin D receptors, including cardiomyocytes,
vascular smooth muscle, and endothelium. 1

145. Rowan T. Chlebowski et al., Calcium Plus Vitamin D Supplementation and the
Risk of Breast Cancer,100 J.NAT'L CANCER INST. 1581, 1581 (2008).
146. Id. at 1586-88.
147. Zittermann, supra note 116, at 486-87.
148. Erin D. Michos & Roger S. Blumenthal, Editorial, Vitamin D Supplementation
and CardiovascularDisease Risk, 115 CIRCULATION 827, 827 (2007).
149. Jessica Kendrick et al., 25-Hydroxyvitamin Deficiency Is Independently
Associated with Cardiovascular Disease in the Third National Health and Nutrition
Examination Survey, 205 ATHEROSCLEROSIS 255, 257 (2009).
150. Thomas J. Wang et al., Vitamin D Deficiency and Risk of Cardiovascular
Disease, 117 CIRCULATION 503, 503 (2008).
151. Id.
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In the Framingham Offspring Study, subjects with low
vitamin D levels had a hazards ratio of 1.62 for myocardial
infarction, heart failure, and coronary insufficiency. 152 In the
Health Professionals Follow-up Study, men with insufficient
vitamin D levels had a relative risk of 2.09 for heart attack
compared with men with sufficient levels. 5 3 Recall the LURIC
coronary angiography study discussed above in which those in
the lowest quartile for vitamin D level had a sixty percent
greater mortality than those in the highest quartile.14
The Women's Health Initiative showed no benefit on
cardiovascular endpoints after vitamin D supplementation in
this large prospective randomized study discussed elsewhere.15
In an editorial in the same journal, Michos speculated that the
dose of vitamin D may have been too low, or that only patients
at high risk for heart disease would benefit. He reminded the
reader of the surprising trials involving antioxidants A, C, and E
where observational studies that demonstrated reduced
cardiovascular risk were not borne out in the randomized
clinical studies.15 6
Vitamin D may regulate blood pressure through the reninangiotensin system. 5 7 In the NHANES III trial, the mean blood
pressure was found to vary inversely with vitamin D levels. The
association was strongest in the elderly.15 In a meta-analysis
Wu used four randomized, controlled trials to examine the
relationship between vitamin D supplementation and blood
pressure. He found that supplementation may lower systolic
blood pressure, but not diastolic pressure.''9
152. Id. at 505.
153. Edward Giovannucci et al., 25-Hydroxyvitanin D and Risk of Myocardial
Infarction in Men, 168 ARCHIVES INTERNAL MED. 1174, 1174 (2008)
154. Dobnig et al., supra note 130, at 1342-43.
155. Judith Hsia et al., Calcium/Vitamin D Supplementation and Cardiovascular
Events, 115 CIRCULATION 846, 846 (2007).
156. Michos & Blumenthal, supra note 148, at 827-28.
157. Robert Scragg et al., Serum 25-hydroxyvitamin D, Ethnicity, and Blood Pressure
in the Third National Health and Nutritional Examination Survey, 20 AM. J.
HYPERTENSION 713, 713 (2007).
158. Id.
159. See gcnerally Sheng Hiu Wu et al., Effects on Vitamin D Supplementation on
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In summary, there is strong epidemiologic evidence for an
association between vitamin D and cardiovascular disease;
however, there is insufficient evidence for supplementation.
There is epidemiologic evidence and basic science to
support a role of vitamin D in multiple sclerosis, diabetes,
cognition and depression; however, the story becomes
repetitive. We have seen that there is a strong association
between vitamin D levels and a number of chronic diseases.
There is increasing basic science research to support the
hypothesis that vitamin D plays a central regulatory role at the
cellular level. However, there is little scientific evidence in the
form of randomized controlled trials to support routine
supplementation beyond the RDA of 400 IU per day.
As if to place an exclamation point on these conclusions, the
prestigious Institute of Medicine released a report on Calcium
and Vitamin D, November 30, 2010. The IOM found that
"evidence supported a role for .

.

. [vitamin D and calcium] in

bone health but not in other health conditions"; the report went
on to state that "emerging evidence [indicates] that too much of
these nutrients may be harmful," challenging the concept that
"more is better." 60
We must recall the lessons learned with hormone
replacement therapy. We conduct the studies because we don't
know the answers.
SUMMARY

More tests and more treatment do not necessarily lead to a better
health outcome; increasingly, less care is better care. The public
is ill-served when assessments of clinical effectiveness are
politicized. Although our society emphasizes screening and
drug treatment to prevent disease, other interventions may be
more important, including sanitation and efforts to maintain a

Blood Pressure, 103 S. Med. J. 729 (Aug. 2010).
160. CoMM. REVIEW DIETARY REFERENCE INTAKES VITAMIN C & CALCIUM, INST.
MED., DIETARY REFERENCE INTAKES FOR CALCIUM AND VITAMIN 1 (2011).
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clean environment, smoking cessation, and weight loss. Despite
the promise of observational studies that subtle vitamin
deficiency states are associated with chronic diseases, there is
little evidence that vitamin supplementation for these conditions
is beneficial and some evidence that supplements are harmful.

